This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Schrödinger (company) | |
|---|---|
| Name | Schrödinger |
| Type | Public |
| Industry | Software, Biotechnology |
| Founded | 1990 |
| Founder | Ramakrishnan "Rama" S. Srinivasan |
| Headquarters | New York City, New York, United States |
| Key people | Richard A. Campeau |
| Revenue | (example) see annual reports |
Schrödinger (company)
Schrödinger is an American software and biotechnology company specializing in molecular modeling, computational chemistry, and drug discovery platforms. Founded in 1990, the company develops physics-based and machine learning-driven tools used by pharmaceutical firms, academic institutions, and chemical companies worldwide. Its operations intersect with firms, universities, research institutes, and funding agencies across the life sciences and informatics sectors.
Schrödinger traces origins to the early computational chemistry efforts of academic groups and national laboratories such as Brookhaven National Laboratory, Argonne National Laboratory, Lawrence Berkeley National Laboratory, and researchers affiliated with Massachusetts Institute of Technology, Harvard University, Stanford University, University of California, Berkeley, Columbia University, Yale University, Princeton University, California Institute of Technology, University of Chicago, University of Pennsylvania, Johns Hopkins University, Cornell University, University of Michigan, University of Texas at Austin, University of California, San Diego, University of Cambridge, University of Oxford, Imperial College London, ETH Zurich, Max Planck Society, and Riken. Early software efforts paralleled developments at companies like DuPont, Pfizer, Merck & Co., GlaxoSmithKline, Roche, Novartis, AstraZeneca, Eli Lilly and Company, Bayer, Sanofi, Takeda Pharmaceutical Company, Johnson & Johnson, AbbVie, Bristol-Myers Squibb, Biogen, Amgen, Genentech, and Gilead Sciences. Over successive decades, the firm navigated market shifts exemplified by events such as the Human Genome Project, the rise of next-generation sequencing, and the expansion of cloud computing led by Amazon Web Services, Microsoft Azure, and Google Cloud Platform. The company completed a public offering and expanded through partnerships with biopharmaceuticals, academic consortia, and venture investors including entities like Third Rock Ventures, Flagship Pioneering, ARCH Venture Partners, NEA (New Enterprise Associates), and regional development organizations. Global activities later linked the firm to research hubs in Boston, New York City, San Francisco Bay Area, Cambridge (UK), Zurich, Munich, Tokyo, Seoul, Shanghai, and Bangalore.
Schrödinger's portfolio integrates physics-based modeling, quantum chemistry, molecular dynamics, and AI tools used alongside platforms from OpenEye Scientific Software, Accelrys, BIOVIA, ChemAxon, Dotmatics, PerkinElmer, Clarivate, Elsevier, Wiley, Springer Nature, Cambridge Crystallographic Data Centre, Protein Data Bank, European Bioinformatics Institute, PubChem, ChEMBL, KEGG, and UniProt. Core software includes molecular docking, free-energy perturbation, force field development, quantum mechanical calculations, and cheminformatics workflows that interface with high-performance computing centers like National Energy Research Scientific Computing Center, Oak Ridge Leadership Computing Facility, Lawrence Livermore National Laboratory, and supercomputers such as Summit (supercomputer). The company also develops cloud-enabled drug discovery platforms that integrate machine learning frameworks inspired by research at Google DeepMind, OpenAI, Facebook AI Research, Deep Genomics, Insilico Medicine, BenevolentAI, Atomwise, Recursion Pharmaceuticals, and algorithmic techniques from groups at Carnegie Mellon University, University of Toronto, University College London, and ETH Zurich. Products are applied in programs targeting therapeutic areas studied by partners at National Institutes of Health, FDA, European Medicines Agency, Wellcome Trust, Bill & Melinda Gates Foundation, Chan Zuckerberg Initiative, and nonprofit research consortia.
The company operates a mixed-model business combining commercial software licenses, cloud subscriptions, software-as-a-service contracts, and drug discovery partnerships and collaborations with biopharmaceutical firms such as Pfizer, Merck, Novartis, AstraZeneca, Roche, GSK, Eli Lilly and Company, Takeda Pharmaceutical Company, Johnson & Johnson, Bristol-Myers Squibb, Amgen, and Gilead Sciences. Revenue streams include enterprise software sales, professional services, collaborative research agreements, milestone payments, and potential royalties from partnered programs. Financial disclosures reference quarterly filings with U.S. Securities and Exchange Commission, investor presentations, and analyst coverage from firms like Goldman Sachs, Morgan Stanley, J.P. Morgan, Bank of America Merrill Lynch, Barclays, Citigroup, and UBS. The company engages with capital markets via stock exchanges and interacts with indices and institutional investors including Vanguard, BlackRock, and Fidelity Investments.
Research collaborations span pharmaceutical companies, biotechnology startups, academic laboratories, and government agencies including National Institutes of Health, Defense Advanced Research Projects Agency, European Research Council, Japan Society for the Promotion of Science, Wellcome Trust, Bill & Melinda Gates Foundation, and multilateral consortia. Academic partnerships include institutions such as Harvard Medical School, Stanford School of Medicine, Yale School of Medicine, University of Cambridge School of Clinical Medicine, Oxford University Clinical Research Unit, MIT Media Lab, Weill Cornell Medicine, Scripps Research, Cold Spring Harbor Laboratory, Broad Institute, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Institut Pasteur, Max Planck Institute for Chemical Physics of Solids, and CNRS. Collaborative programs address targets discovered in oncology, infectious disease, neuroscience, and immunology and have produced joint publications in journals like Nature, Science, Cell, PNAS, Nature Medicine, Nature Biotechnology, Journal of the American Chemical Society, Angewandte Chemie, and Journal of Chemical Theory and Computation.
Corporate leadership has included executives and board members with experience from biotechnology and pharmaceutical firms and academic institutions such as Genentech, Amgen, Merck, Pfizer, Novartis, AstraZeneca, Eli Lilly and Company, Bristol-Myers Squibb, Johnson & Johnson, Harvard University, Stanford University, MIT, Yale University, and Columbia University. The board oversees corporate strategy, compliance with securities regulators like the U.S. Securities and Exchange Commission, and interactions with institutional investors including BlackRock, Vanguard, and State Street Corporation. Governance practices reflect standards promoted by organizations such as National Association of Corporate Directors and are informed by exchanges and markets including New York Stock Exchange and NASDAQ.
The company and its software have been recognized by industry and academic awards and cited in research honored by organizations like Royal Society of Chemistry, American Chemical Society, International Society for Computational Biology, Society for Biomolecular Sciences, Biophysical Society, European Federation for Medicinal Chemistry, Gordon Research Conferences, Lasker Foundation, Breakthrough Prize, Royal Society, National Academy of Sciences, National Academy of Engineering, and regional innovation awards from entities such as MassMEP and NYCEDC.
Category:Software companies Category:Biotechnology companies